Metabolic myocardial protection in children with anthracycline cardiomyopathy
T.V. Shatynska, O.B. Synoverska
The article presents results of an investigation of the heart’s systolic function and level of an atrial natriuretic peptide as a marker of heart failure in children with acute lymphoblastic leukemia and developed anthracycline cardiomyopathy as a result of chemotherapy protocol with doxorubicin. Distribution of children into groups conducted with regard to the use of cardioprotective metabolic therapy with medicinal product, in which the levocarnitine was an active substance. The first group of patients was cardioprotected and the second was not. Specified drug therapy began at the 39th day of the first phase of I protocol of the treatment of acute lymphoblastic leukemia and lasted till the end of I and mM protocols, and 2 weeks before the first phase II protocol. Assessment of systolic heart function was studied using echocardioscopy. Diagnosis of early signs of heart failure was made by determining the level of atrial natriuretic peptide. It was established that the cardioprotective therapy with medicinal product, in which the levocarnitine was an active substance, increases the contractile ability of the left ventricle, and also reduces the manifestations of systolic dysfunction and the level of heart failure marker.
How to cite this article:
T.V. Shatynska, O.B. Synoverska. Metabolic myocardial protection in children with anthracycline cardiomyopathy. Pharma Innovation 2015;4(6):64-69.